Phase II open-label, multi-centre study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: James Lorens, Carlos Eduardo Arce-Lara, Edurne Arriola, Paal Brunsvig, Enric Carcereny Costa, Manuel Domine, Konstantin H. Dragnev, Enriqueta Felip, Rosario Garcia Campelo, Matthew Krebs, Santiago Ponce Aix, James F. Spicer, Jose Manuel Trigo Perez, Nuria Vinolas, Robert J Holt, Anthony Brown, Michael Jon Chisamore
Institutions: BerGenBio (Norway), Medical College of Wisconsin, Hospital Del Mar, Oslo University Hospital, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Hospital Universitario Fundación Jiménez Díaz, Dartmouth–Hitchcock Medical Center, Vall d'Hebron Hospital Universitari, Complexo Hospitalario Universitario A Coruña, Manchester Academic Health Science Centre, University of Manchester, The Christie NHS Foundation Trust, Hospital Universitario 12 De Octubre, King's College London, Hospital Clínico Universitario Virgen de la Victoria, Hospital Clínic de Barcelona, Merck & Co., Inc., Rahway, NJ, USA (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2889619501